Patiromer治疗血液透析患者高钾血症的真实世界评估
基于美国大型透析机构电子健康记录(2015–2016年)的回顾性队列研究,纳入527例Patiromer、852例SPS及8747例无钾结合剂的高钾血症血液透析患者。Patiromer启动者既往多次高钾血症风险更高(OR 2.6),用药后血钾平均降低约0.5 mEq/L,K+≥6.0 mEq/L比例由48%降至22%(P<0.001)。
要点
- Patiromer启动者既往多次高钾血症风险为对照的2.6倍(OR 2.6, 95%CI 1.8–3.7)。
- 61%患者起始剂量为8.4 g每日一次,60%首张处方180天后仍开放。
- 用药后血钾平均降低约0.5 mEq/L,K+≥6.0 mEq/L比例由48%降至22%(P<0.001)。
核心结论
- 慢性血液透析患者中,启动Patiromer者基线高钾血症更严重且控制不佳。
- 长期Patiromer使用与血钾显著降低相关。
研究设计与样本
- 纳入有Patiromer、SPS医嘱或实验室高钾血症证据(无钾结合剂队列)的血液透析患者,中位随访141天。
主要发现
- 研究队列包括527例Patiromer、852例SPS和8747例无钾结合剂患者。
- Patiromer启动者既往多次高钾血症的比值比为2.6(95%CI 1.8–3.7)。
- 61%患者起始剂量为8.4 g每日一次,60%患者首张Patiromer医嘱在180天后仍开放。
- Patiromer启动后血钾平均降低约0.5 mEq/L,K+≥6.0 mEq/L比例由48%降至22%(P<0.001)。
临床怎么用
- 对于慢性血液透析且反复高钾血症的患者,可考虑使用Patiromer以降低血钾。
- 真实世界中Patiromer常以8.4 g每日一次起始,且多数患者长期使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patiromer is a potassium (K+) binding polymer indicated for treating hyperkalemia. Among patients receiving chronic hemodialysis (HD), this study aimed to identify patient characteristics associated with patiromer initiation, describe patiromer utilization, and analyze serum K+ pre- and post-patiromer initiation. METHODS: In a retrospective cohort study, using electronic health record data from a large dialysis provider in the United States (study period: December 21, 2015, to December 20, 2016), HD patients were included who had a medication order for patiromer, sodium polystyrene sulfonate (SPS), or laboratory evidence of hyperkalemia (no K+ binder [NoKb] cohort). The index date was the first order for patiromer/SPS, or the first K+ ≥5.0 mEq/l (NoKb cohort), respectively. Using multivariable logistic regression, we identified patient characteristics associated with patiromer initiation. We evaluated patiromer utilization using Kaplan-Meier methodology and proportion of days covered. Serum K+ concentrations were assessed pre- versus post-patiromer initiation. RESULTS: Study cohorts included 527 (patiromer), 852 (SPS), and 8747 (NoKb) HD patients. Median follow-up was 141 days. Patiromer initiators were 2.6 times more likely to have had multiple prior episodes of hyperkalemia (odds ratio [OR]: 2.6; 95% confidence interval [CI]: 1.8-3.7). Most (61%) commenced patiromer on 8.4 g once daily; 60% of patients' first patiromer order remained open after 180 days. Statistically significant reductions in K+, averaging approximately -0.5 mEq/l, were observed post-patiromer initiation (48% pre-patiromer vs. 22% post-patiromer had K+ ≥6.0 mEq/l [P < 0.001]). CONCLUSION: Patiromer initiators receiving chronic hemodialysis had comparatively more severe, uncontrolled baseline hyperkalemia. Medication order data show long-term patiromer use was associated with significantly reduced K+.
引用
- Kovesdy CP, Rowan CG, Conrad A, et al. Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients. Kidney Int Rep. 2018. PMID: 30775627. doi:10.1016/j.ekir.2018.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。